NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs.
about
Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantationGranulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis.SOCS3 regulates graft-versus-host disease.Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignanciesInvariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.Epidermal growth factor attenuates tubular necrosis following mercuric chloride damage by regeneration of indigenous, not bone marrow-derived cellsRapid Functional Decline of Activated and Memory Graft-versus-Host-Reactive T Cells Encountering Host Antigens in the Absence of Inflammation.Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease.Pathophysiology of acute graft-versus-host disease: recent advances.Invariant NKT cells increase drug-induced osteosarcoma cell death.HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen.Advances in the understanding of acute graft-versus-host disease.CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.Mouse models of bone marrow transplantationInvariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration.Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant.Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges.New perspectives on the biology of acute GVHD.New G-CSF agonists for neutropenia therapy.Recent advances on cellular therapies and immune modulators for graft-versus-host disease.Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival.Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression.Immunotherapeutic strategies targeting natural killer T cell responses in cancer.Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease.Reconstitution of maturating and regulatory lymphocyte subsets after cord blood and BMT in children.Mixed Signals: Co-Stimulation in Invariant Natural Killer T Cell-Mediated Cancer Immunotherapy.Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients.Pre-transplant donor CD4− invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host diseaseHuman CD4- invariant NKT lymphocytes regulate graft versus host disease
P2860
Q33758318-D7A56093-BA1B-4A7A-B880-AF08F4191B23Q33780538-E988ACD8-E4DD-4AD2-9167-E917A2E2399FQ34022451-C2C09FE6-9C1B-4BF2-B1AC-FFACDD2F45EFQ34353567-6703F8E4-3386-4CB0-9385-73D57F6BAC73Q34431441-C487071B-DB0F-436B-961B-3588CDDD41D8Q35127172-8787D368-C398-49C5-AE32-747B436097CBQ35531378-905D498A-2C11-4E5A-B729-0D75E268DDD2Q35864495-F47934C7-AC8B-44DB-959A-3BA0010E6ABFQ35894369-78D17608-41AF-45B2-BD50-ADBC9C88B410Q36156559-ACFCBE29-8A93-4193-9F3D-8C023DE887CFQ36446525-B559285D-0F61-476D-8129-8C8F28D1C950Q36534267-966DC196-CFEB-4756-B6FB-A5A9182EAB40Q36759581-8484301D-54A7-43AD-A30C-5194625F20C5Q36951719-497CD629-F685-41D4-A366-221D862114B7Q37045969-18C2FB5E-EF42-4564-AE69-0EFE4E5E061AQ37237496-D74AF12F-F65F-479D-94AC-C361B6747EE0Q37258220-9E549D9F-E061-465D-BE83-EBA80A91E42BQ37388427-EF31415A-B3A6-44B6-A8AE-418B3013DE0AQ37641063-5B1ECA24-4BA2-42EF-B6B5-29C48799A291Q38145338-06392EEC-A7DC-4AC1-A7A3-20F02F416791Q38246755-C8E2D2FC-8863-4D14-8371-502E5DA61C14Q38570464-7E0F5BAC-86BD-4E79-ACF2-B39FA7B2D02BQ38666579-61A2183B-EE3B-48A3-9F52-AB62BD479AC7Q38734173-28AF12C2-8810-4D1B-932C-6967E5D73FB5Q38890717-7D0A3E89-40CD-43A6-86CF-83CD570C9A43Q44925138-0BCC3756-4B38-4C72-9A25-C334963933C6Q45403029-E69B7B88-1301-4BD6-AB36-C1FAEB2C9241Q47094171-75EBB5D0-19C7-4CF4-90B2-EB2999FF514AQ47764462-CFEBC5B3-A1DB-4CE7-BAD2-7B6A3C2ACF2CQ57216449-11A6206B-8436-465D-9687-2512EE3D69B4Q58129678-81E14C8B-D4CB-4A96-9463-348425382ADD
P2860
NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
NKT cell-dependent leukemia er ...... ion with potent G-CSF analogs.
@ast
NKT cell-dependent leukemia er ...... ion with potent G-CSF analogs.
@en
NKT cell-dependent leukemia er ...... ion with potent G-CSF analogs.
@nl
type
label
NKT cell-dependent leukemia er ...... ion with potent G-CSF analogs.
@ast
NKT cell-dependent leukemia er ...... ion with potent G-CSF analogs.
@en
NKT cell-dependent leukemia er ...... ion with potent G-CSF analogs.
@nl
prefLabel
NKT cell-dependent leukemia er ...... ion with potent G-CSF analogs.
@ast
NKT cell-dependent leukemia er ...... ion with potent G-CSF analogs.
@en
NKT cell-dependent leukemia er ...... ion with potent G-CSF analogs.
@nl
P2093
P2860
P50
P356
P1476
NKT cell-dependent leukemia er ...... tion with potent G-CSF analogs
@en
P2093
Alistair L J Don
Angela C Burman
Edward S Morris
Helen M Bofinger
Rachel D Kuns
Steven A Porcelli
Stuart D Olver
Tatjana Banovic
Vanessa Rowe
P2860
P304
P356
10.1172/JCI25249
P407
P577
2005-10-13T00:00:00Z